MET and non-small cell lung carcinoma: Dysregulation of the mesenchymal-epithelial transition factor or MET (also known as hepatocyte growth factor [HGF] receptor) signaling pathway has been implicated in numerous studies as a key contributor in cancer biology including proliferation, metastasis and resistance to therapy in non-small cell lung cancers (NSCLC), colorectal cancers (CRC), and head and neck cancers (HNSCC) [12–15].